Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
The ruling applies to patients who are less than one year from completing treatment with Roche’s Herceptin (trastuzumab) following surgery, where Herceptin is the only HER2-directed therapy the patient has received. It has been estimated that this means that around 1,600 people in England and Wales will be eligible to receive the therapy.
